Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease

Bibliography

• Brown EA, Muir RD, Cella JA. Steroidal aldosterone blockers. II. J Org Chem 1959;24:1109-19
   Web of Science ®Google Scholar
• Greenblatt DJ, Koch-Weser J. Gynecomastia and impotence: Complications of spironolactone therapy. JAMA 1973;223(1):82
   PubMed Web of Science ®Google Scholar
• Corvol P, Michaud A, Menard J, et al. Antiandrogenic effect of spirolactones: Mechanism of action. Endocrinology 1975;97(1):52-8
   PubMed Web of Science ®Google Scholar
• Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004;217(1-2):27-31
   PubMed Web of Science ®Google Scholar
• Hu X, Li S, McMahon EG, et al. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev Med Chem 2005;5(8):709-18
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364(1):11-21
   PubMed Web of Science ®Google Scholar
• Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46(3):425-31
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized aldactone evaluation study investigators. N Engl J Med 1999;341(10):709-17
   PubMed Web of Science ®Google Scholar
• Ma TK, Szeto CC. Mineralocorticoid receptor antagonist for renal protection. Ren Fail 2012;34(6):810-17
   PubMed Web of Science ®Google Scholar
• Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41(1):64-8
   PubMed Web of Science ®Google Scholar
• van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006;24(11):2285-92
   PubMed Web of Science ®Google Scholar
• Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease. Kidney Int 2011;79(10):1051-60
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309-21
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart failure survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. Eur Heart J 2006;27(22):2725-36
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Dahlstrom U, Filippatos G, et al. EURObservational research programme: The heart failure pilot survey (ESC-HF pilot). Eur J Heart Fail 2010;12(10):1076-84
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Yancy CW, Albert NM, et al. Heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF. Circ Heart Fail 2008;1(2):98-106
   PubMed Web of Science ®Google Scholar
• Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA 2009;302(15):1658-65
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Ambardekar AV, Kaltenbach L, et al. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from get with the guidelines-heart failure). Am J Cardiol 2011;107(12):1818-23
   PubMed Web of Science ®Google Scholar
• Samuel JL, Delcayre C. Heart failure: Aldosterone antagonists are underused by clinicians. Nat Rev Cardiol 2010;7(3):125-7
   PubMed Web of Science ®Google Scholar
• Funder JW. Mineralocorticoid-receptor blockade, hypertension and heart failure. Nat Clin Pract Endocrinol Metab 2005;1(1):4-5
   PubMedGoogle Scholar
• Eschalier R, McMurray JJ, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: Analyses of the EMPHASIS-HF study subgroups (eplerenone in mild patients hospitalization and SurvIval study in heart failure). J Am Coll Cardiol 2013;62(17):1585-93
   PubMed Web of Science ®Google Scholar
• Collier TJ, Pocock SJ, McMurray JJ, et al. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: Insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J 2013;34(36):2823-9
   PubMed Web of Science ®Google Scholar
• Barfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012;7(8):1385-403
   PubMed Web of Science ®Google Scholar
• Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003;88(6):2364-72
   PubMed Web of Science ®Google Scholar
• Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes 2010;17(3):199-204
   PubMed Web of Science ®Google Scholar
• Nguyen Dinh Cat A, Jaisser F. Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens 2012;21(2):147-56
   PubMed Web of Science ®Google Scholar
• Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006;47(3):312-18
   PubMed Web of Science ®Google Scholar
• Gunaruwan P, Schmitt M, Taylor J, et al. Lack of rapid aldosterone effects on forearm resistance vasculature in health. J Renin Angiotensin Aldosterone Syst 2002;3(2):123-5
   PubMed Web of Science ®Google Scholar
• Gunaruwan P, Schmitt M, Sharman J, et al. Effects of aldosterone on forearm vasculature in treated chronic heart failure. Am J Cardiol 2005;95(3):412-14
   PubMed Web of Science ®Google Scholar
• Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 2008;12(4):233-42
   PubMed Web of Science ®Google Scholar
• Nishiyama A, Yao L, Fan Y, et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005;45(4):710-16
   PubMed Web of Science ®Google Scholar
• Nagai Y, Miyata K, Sun GP, et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 2005;46(4):1039-45
   PubMed Web of Science ®Google Scholar
• Shibata S, Nagase M, Yoshida S, et al. Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk1. Hypertension 2007;49(2):355-64
   PubMed Web of Science ®Google Scholar
• Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004;351(1):33-41
   PubMed Web of Science ®Google Scholar
• Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48(11):2293-300
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40(6):892-6
   PubMed Web of Science ®Google Scholar
• Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345(23):1689-97
   PubMed Web of Science ®Google Scholar
• Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006;295(22):2638-45
   PubMed Web of Science ®Google Scholar
• Pitt B. “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovasc Drugs Ther 1995;9(1):145-9
   PubMed Web of Science ®Google Scholar
• Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91(3):457-65
   PubMed Web of Science ®Google Scholar
• Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003;16(9 Pt 1):781-8
   PubMed Web of Science ®Google Scholar
• Cicoira M, Zanolla L, Rossi A, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001;37(7):1808-12
   PubMed Web of Science ®Google Scholar
• Schjoedt KJ, Andersen S, Rossing P, et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004;47(11):1936-9
   PubMed Web of Science ®Google Scholar
• Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41(1):64-8
   PubMed Web of Science ®Google Scholar
• Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001;29(1):13-21
   PubMed Web of Science ®Google Scholar
• Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007;3(9):486-92
   PubMedGoogle Scholar
• Delbeck M, Kretschmer A, Kast R, et al. Cardiorenal protection by BAY 94-8862, a novel mineralocorticoid receptor antagonist in a preclinical model of hypertension and diastolic heart Failure (abstract)
   Google Scholar
• Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014;64(1):69-78
   PubMed Web of Science ®Google Scholar
• Lentini S, Kimmeskamp-Kirschbaum N, Wensing G, Heining R. BAY 94-8862 exerts a potent natriuretic effect in healthy male subjects pre-treated with fludrocortisone: Findings from a proof-of-concept study (abstract)
   Google Scholar
• Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J 2013;34(31):2453-63
   PubMed Web of Science ®Google Scholar
• Overdiek HW, Hermens WA, Merkus FW. New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther 1985;38(4):469-74
   PubMed Web of Science ®Google Scholar
• Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Mol Cell Endocrinol 2012;350(2):310-17
   PubMed Web of Science ®Google Scholar
• Cook CS, Berry LM, Bible RH, et al. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos 2003;31(11):1448-55
   PubMed Web of Science ®Google Scholar
• Review and evaluation of pharmacology and toxicology data INSPRA [Internet]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-437S002_Inspra_Pharmr.pdf
   Google Scholar
• Label information ALDACTONE [Internet]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/012151s072lbl.pdf
   Google Scholar
• Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281(2):H647-54
   PubMed Web of Science ®Google Scholar
• Fraccarollo D, Galuppo P, Hildemann S, et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003;42(9):1666-73
   PubMed Web of Science ®Google Scholar
• Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283(5):H1802-10
   PubMed Web of Science ®Google Scholar
• Brandish PE, Forest TW, Chen H, et al. Eplerenone decreases inflammatory foci in spontaneously hypertensive rat hearts with minimal effects on blood pressure. J Cardiovasc Pharmacol 2009;53(1):44-51
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. developed in collaboration with the heart failure association (HFA) of the ESC. Eur J Heart Fail 2012;14(8):803-69
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of ARTS: A randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 2012;14(6):668-75
   PubMed Web of Science ®Google Scholar
• Park CW. Diabetic kidney disease: From epidemiology to clinical perspectives. Diabetes Metab J 2014;38(4):252-60
   PubMedGoogle Scholar
• Fioretto P, Barzon I, Mauer M. Is diabetic nephropathy reversible? Diabetes Res Clin Pract 2014;104(3):323-8
   PubMed Web of Science ®Google Scholar
• Adler S. Diabetic nephropathy: Linking histology, cell biology, and genetics. Kidney Int 2004;66(5):2095-106
   PubMed Web of Science ®Google Scholar
• Nagase M, Shibata S, Yoshida S, et al. Podocyte injury underlies the glomerulopathy of dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006;47(6):1084-93
   PubMed Web of Science ®Google Scholar
• Shibata S, Nagase M, Yoshida S, et al. Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk1. Hypertension 2007;49(2):355-64
   PubMed Web of Science ®Google Scholar
• Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: Implication in proteinuric kidney disease. Nat Med 2008;14(12):1370-6
   PubMed Web of Science ®Google Scholar
• Mundel P, Reiser J. Proteinuria: An enzymatic disease of the podocyte? Kidney Int 2010;77(7):571-80
   PubMed Web of Science ®Google Scholar
• Briet M, Schiffrin EL. Aldosterone: Effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010;6(5):261-73
   PubMed Web of Science ®Google Scholar
• Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996;98(4):1063-8
   PubMed Web of Science ®Google Scholar
• Nishiyama A, Yao L, Nagai Y, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004;43(4):841-8
   PubMed Web of Science ®Google Scholar
• Ma J, Weisberg A, Griffin JP, et al. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 2006;69(6):1064-72
   PubMed Web of Science ®Google Scholar
• Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006;17(5):1362-72
   PubMed Web of Science ®Google Scholar
• Taira M, Toba H, Murakami M, et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol 2008;589(1-3):264-71
   PubMed Web of Science ®Google Scholar
• Fujisawa G, Okada K, Muto S, et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004;66(4):1493-502
   PubMed Web of Science ®Google Scholar
• Guo C, Martinez-Vasquez D, Mendez GP, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006;147(11):5363-73
   PubMed Web of Science ®Google Scholar
• Kang YS, Ko GJ, Lee MH, et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 2009;24(1):73-84
   PubMed Web of Science ®Google Scholar
• Mavrakanas TA, Cheva A, Kallaras K, et al. Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats. Pharmacology 2010;86(2):85-91
   PubMed Web of Science ®Google Scholar
• Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005;68(6):2829-36
   PubMed Web of Science ®Google Scholar
• Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 2005;28(9):2106-12
   PubMed Web of Science ®Google Scholar
• Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006;70(3):536-42
   PubMed Web of Science ®Google Scholar
• Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1(5):940-51
   PubMed Web of Science ®Google Scholar
• Saklayen MG, Gyebi LK, Tasosa J, Yap J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: Results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med 2008;56(4):714-19
   PubMed Web of Science ®Google Scholar
• Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009;20(12):2641-50
   PubMed Web of Science ®Google Scholar
• Nielsen SE, Persson F, Frandsen E, et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: A randomized placebo-controlled crossover study. Diabet Med 2012;29(8):e184-90
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Noshad S, Jarrah S, et al. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: A randomized clinical trial. Nephrol Dial Transplant 2013;28(11):2823-33
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Agarwal R, Chan JC, et al. Effect of finerenone in patients with diabetic Nephropathy (abstract). World Congress of Nephrology, 13–17 March 2015, Cape Town, South Africa; 2015
   Google Scholar
• Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 2000;160(5):685-93
   PubMed Web of Science ®Google Scholar
• Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011;80(3):282-7
   PubMed Web of Science ®Google Scholar
• Youn JH, McDonough AA. Recent advances in understanding integrative control of potassium homeostasis. Annu Rev Physiol 2009;71:381-401
   PubMed Web of Science ®Google Scholar
• Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol 2014;10(11):653-62
   PubMed Web of Science ®Google Scholar
• Salem MM, Rosa RM, Batlle DC. Extrarenal potassium tolerance in chronic renal failure: Implications for the treatment of acute hyperkalemia. Am J Kidney Dis 1991;18(4):421-40
   PubMed Web of Science ®Google Scholar
• van Ypersele de Strihou C. Potassium homeostasis in renal failure. Kidney Int 1977;11(6):491-504
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351(6):543-51
   PubMed Web of Science ®Google Scholar
• Piotrowski DW. Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. J Med Chem 2012;55(18):7957-66
   PubMed Web of Science ®Google Scholar
• Liamis G, Liberopoulos E, Barkas F, Elisaf M. Diabetes mellitus and electrolyte disorders. World J Clin Cases 2014;2(10):488-96
   PubMed Web of Science ®Google Scholar
• Vardeny O, Claggett B, Anand I, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014;7(4):573-9
   PubMed Web of Science ®Google Scholar
• Rossignol P, Cleland JG, Bhandari S, et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: Insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study. Circulation 2012;125(2):271-9
   PubMed Web of Science ®Google Scholar
• Rossignol P, Dobre D, McMurray JJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: Results from the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF). Circ Heart Fail 2014;7(1):51-8
   PubMed Web of Science ®Google Scholar
• Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372(3):211-21
   PubMed Web of Science ®Google Scholar
• Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015;372(3):222-31
   PubMed Web of Science ®Google Scholar
• Kolkhof P, Kretschmer A, Baerfacker L, et al. Improved survival and nephroprotection in hypertensive rats by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist (abstract)
   Google Scholar
• Albrecht-Kupper B, Kretschmer A, Kast R, et al. Pronounced cardiac protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical model of heart failure (abstract)
   Google Scholar